Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.

MLA

Liu, Zheng, et al. “Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.” Journal of Crohn’s & Colitis, vol. 16, no. 12, Dec. 2022, pp. 1835–44. EBSCOhost, https://doi.org/10.1093/ecco-jcc/jjac093.

APA

Liu, Z., Julsgaard, M., Zhu, X., Martin, J., Barclay, M. L., Cranswick, N., Gibson, P. R., Gearry, R. B., van der Giessen, J., Connor, S. J., Rosella, O., Grosen, A., Toong, C., Flanagan, E., Wieringa, J. W., Woude, C. J. van der, Bell, S. J., & Group, T. C. S. (2022). Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children. Journal of Crohn’s & Colitis, 16(12), 1835–1844. https://doi.org/10.1093/ecco-jcc/jjac093

Chicago

Liu, Zheng, Mette Julsgaard, Xiao Zhu, Jennifer Martin, Murray L Barclay, Noel Cranswick, Peter R Gibson, et al. 2022. “Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.” Journal of Crohn’s & Colitis 16 (12): 1835–44. doi:10.1093/ecco-jcc/jjac093.